ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving ABT-888 together with
radiation therapy and temozolomide may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of ABT-888 when
given together with radiation therapy and temozolomide and to see how well it works in
treating patients with newly diagnosed glioblastoma multiforme.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins